Trials / Terminated
TerminatedNCT03866798
Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)
Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Octapharma · Industry
- Sex
- All
- Age
- 1 Year – 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open-label, single-arm, multicenter, Phase 4 study evaluating the efficacy and safety of PANZYGA in pediatric patients with chronic ITP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Panzyga | Immune Globulin, intravenous, human-ifas |
Timeline
- Start date
- 2020-01-21
- Primary completion
- 2023-09-19
- Completion
- 2024-05-17
- First posted
- 2019-03-07
- Last updated
- 2024-09-24
- Results posted
- 2024-08-07
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03866798. Inclusion in this directory is not an endorsement.